Mayne Pharma Lands First Outside Client for Its US Drug Distribution Platform
DistributeRx lands first third-party partnership with Resilia Pharmaceuticals
Mayne Pharma Group Limited (ASX: MYX) has announced that DistributeRx LLC, its wholly owned subsidiary, has entered into its first third-party commercial partnership, with Resilia Pharmaceuticals. The agreement sees DistributeRx exclusively distribute RECEDO® topical gel through its prescription distribution platform, with the company earning a fixed fee per RECEDO® prescription filled. The deal positions DistributeRx as a scalable commercial platform capable of generating revenue beyond Mayne Pharma’s own product portfolio.
When big ASX news breaks, our subscribers know first
What the Resilia deal means for DistributeRx and Mayne Pharma investors
RECEDO® topical gel is intended for the management of old and new hypertrophic or keloid scarring resulting from burns, general surgical procedures, or trauma wounds. It is positioned among the most widely recommended scar gels and wound healing agents in the United States.
Resilia Pharmaceuticals, Inc.® is an Atlanta, Georgia-based pharmaceutical company dedicated to the acquisition and growth of branded, generic, and over-the-counter pharmaceutical products. The company has identified plastic surgery, including Mohs surgery procedures, and OBGYN, specifically post-Caesarean section treatment, as its priority prescriber channels for expanding RECEDO®’s reach.
Key commercial terms of the partnership include:
- Exclusive distribution of RECEDO® through the DistributeRx platform
- Fixed fee per prescription filled via the DistributeRx solution
- Expected to deliver the most cost-effective outcome for the product and patients
- Expands patient access to RECEDO® across the United States
Daniel Moore, President of DistributeRx
“We are pleased to enter into this agreement with Resilia Pharmaceuticals for the distribution of RECEDO® topical gel. Scar management is a category where patients have historically had limited effective options, and the RECEDO® profile positions it well to meet that demand.”
Harsha Murthy, Executive Chairman of the Board of Resilia Pharmaceuticals
“DistributeRx brings the commercial infrastructure and market reach that RECEDO® deserves. This partnership is an important step in Resilia’s plans to expand RECEDO®’s use among prescribers…”
Understanding DistributeRx — and why a first third-party deal matters
DistributeRx is a healthcare solutions company that partners with pharmaceutical manufacturers to streamline the prescription distribution process and expand patient access to medications. Its services span strategic access programmes, product support, and pharmacy services, all aimed at improving accessibility for prescribers and patients.
The strategic distinction for investors lies in DistributeRx’s platform model. Unlike a traditional pharmaceutical business that earns revenue only from its own products, DistributeRx generates income each time any manufacturer’s prescription is filled through its infrastructure. The platform’s value grows as more manufacturers adopt it, regardless of whether those products belong to Mayne Pharma.
Notably, the Resilia partnership is the platform’s first third-party client, secured just three months after launch. Daniel Moore described platform growth as “significant” and “ahead of expectations” at this early stage, indicating early commercial traction. For Mayne Pharma investors, the Resilia deal serves as proof-of-concept that external manufacturers are willing to pay to access the platform, providing a pathway to diversify group revenue beyond its own product range.
| Feature | Detail | Relevance to Investors | Status |
|---|---|---|---|
| Platform type | Prescription distribution and patient access infrastructure | Scalable model that earns revenue from multiple manufacturers | Operational |
| Revenue model | Fixed fee per prescription filled | Volume-driven income stream; grows with prescription uptake | Active |
| Ownership structure | Wholly owned subsidiary of Mayne Pharma Group Limited (ASX: MYX) | Revenue flows directly to Mayne Pharma | Confirmed |
| Launch timeline | Approximately three months prior to this announcement | Early growth described as “ahead of expectations” | Post-launch |
| Resilia partnership | Exclusive distribution of RECEDO® topical gel | First third-party client; validates external commercial demand | Announced 1 June 2026 |
The next major ASX story will hit our subscribers first
What comes next — pipeline and platform growth outlook
Daniel Moore signalled a clear commercial roadmap for DistributeRx, stating the company looks forward to working with “more manufacturers into the future” to assist with patient reach and access through its platform. That commentary points to a deliberate pipeline-building strategy rather than a one-off arrangement.
The platform’s early trajectory is notable. Just three months post-launch, Moore described growth as “significant” and “ahead of expectations,” suggesting the business is tracking ahead of internal targets. Key near-term catalysts investors should monitor include:
- Additional third-party manufacturer partnerships being announced
- Prescription volume growth from the RECEDO® rollout across plastic surgery and OBGYN prescriber channels
- Broader expansion of DistributeRx’s client base, which would further validate the platform thesis
These developments sit within Mayne Pharma’s broader positioning as an ASX-listed specialty pharma company and a leader in dermatology and women’s health in the United States. The DistributeRx platform adds a distribution-layer revenue stream that complements the company’s existing commercialisation activities. Investors will be watching whether the pace of new third-party partnerships accelerates as the platform matures and builds its track record in the market.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 subscribers already rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to get the next big healthcare update the moment it drops.